As advised via PHARMAC Tender Results of 30 April 2019 there is to be a change in the listing and future sole supply of Lidocaine gel 2% 10 ml urethral syringe.

New listing from 1 June 2019 (currently a dual listing)

Cathejell gel 2% 10 ml urethral syringe, 25 prefilled syringes                                      Pharmacode 2526360                    Schedule price $105.00 (down from $160.00)

Incumbent brand  (currently a dual listing)

Lidocaine Pfizer gel 2% 10 ml urethral syringe, 10 prefilled syringes                        Pharmacode 2351277                    Schedule price $81.50

HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 November 2019.

Brand switch fee for Community Pharmacy not advised.

As of the date of this notification ProPharma / PWR cannot accept Lidocaine Pfizer gel 2% 10 for credit under any circumstances.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 November 2019. Failure to do so may prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 November 2019 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author